nodes	percent_of_prediction	percent_of_DWPC	metapath
Bortezomib—CYP1A1—Clonidine—glaucoma	0.0461	0.0967	CbGbCtD
Bortezomib—CYP2D6—Carteolol—glaucoma	0.0459	0.0962	CbGbCtD
Bortezomib—CYP1A2—Betaxolol—glaucoma	0.0376	0.0788	CbGbCtD
Bortezomib—CYP2D6—Betaxolol—glaucoma	0.031	0.065	CbGbCtD
Bortezomib—CYP2C19—Methazolamide—glaucoma	0.0309	0.0648	CbGbCtD
Bortezomib—CYP2C9—Diclofenamide—glaucoma	0.0298	0.0625	CbGbCtD
Bortezomib—CYP2C9—Dorzolamide—glaucoma	0.0288	0.0604	CbGbCtD
Bortezomib—CYP2C19—Timolol—glaucoma	0.0263	0.0551	CbGbCtD
Bortezomib—CYP2C9—Methazolamide—glaucoma	0.0257	0.0538	CbGbCtD
Bortezomib—CYP2D6—Methazolamide—glaucoma	0.0235	0.0492	CbGbCtD
Bortezomib—CYP3A4—Pilocarpine—glaucoma	0.0221	0.0463	CbGbCtD
Bortezomib—CYP1A2—Clonidine—glaucoma	0.0206	0.0432	CbGbCtD
Bortezomib—CYP2D6—Timolol—glaucoma	0.02	0.0419	CbGbCtD
Bortezomib—CYP3A4—Brinzolamide—glaucoma	0.0173	0.0364	CbGbCtD
Bortezomib—CYP2D6—Clonidine—glaucoma	0.017	0.0356	CbGbCtD
Bortezomib—CYP3A4—Dorzolamide—glaucoma	0.0167	0.0351	CbGbCtD
Bortezomib—CYP3A4—Methazolamide—glaucoma	0.0149	0.0313	CbGbCtD
Bortezomib—CYP3A4—Acetazolamide—glaucoma	0.0119	0.025	CbGbCtD
Bortezomib—CYP3A4—Clonidine—glaucoma	0.0108	0.0226	CbGbCtD
Bortezomib—PSMD2—Hydrochlorothiazide—Diclofenamide—glaucoma	0.00436	1	CbGdCrCtD
Bortezomib—CTSG—connective tissue—glaucoma	0.00276	0.129	CbGeAlD
Bortezomib—PSMA1—connective tissue—glaucoma	0.00265	0.124	CbGeAlD
Bortezomib—PSMD1—eye—glaucoma	0.00231	0.108	CbGeAlD
Bortezomib—PSMD1—retina—glaucoma	0.00229	0.107	CbGeAlD
Bortezomib—Lacosamide—CA1—glaucoma	0.00214	0.569	CrCbGaD
Bortezomib—PSMD2—eye—glaucoma	0.00204	0.0958	CbGeAlD
Bortezomib—PSMD2—retina—glaucoma	0.00203	0.0949	CbGeAlD
Bortezomib—Lacosamide—CA2—glaucoma	0.00162	0.431	CrCbGaD
Bortezomib—PSMB1—eye—glaucoma	0.00157	0.0735	CbGeAlD
Bortezomib—PSMB2—eye—glaucoma	0.00153	0.0717	CbGeAlD
Bortezomib—PSMB2—retina—glaucoma	0.00152	0.0711	CbGeAlD
Bortezomib—PSMB2—connective tissue—glaucoma	0.00147	0.0691	CbGeAlD
Bortezomib—PTGS1—endothelium—glaucoma	0.000806	0.0378	CbGeAlD
Bortezomib—PTGS1—connective tissue—glaucoma	0.000381	0.0179	CbGeAlD
Bortezomib—Dyspepsia—Pilocarpine—glaucoma	9.65e-05	0.00029	CcSEcCtD
Bortezomib—Chills—Betaxolol—glaucoma	9.63e-05	0.00029	CcSEcCtD
Bortezomib—Syncope—Clonidine—glaucoma	9.62e-05	0.000289	CcSEcCtD
Bortezomib—Arrhythmia—Betaxolol—glaucoma	9.59e-05	0.000288	CcSEcCtD
Bortezomib—Feeling abnormal—Dorzolamide—glaucoma	9.56e-05	0.000288	CcSEcCtD
Bortezomib—Decreased appetite—Pilocarpine—glaucoma	9.53e-05	0.000287	CcSEcCtD
Bortezomib—Feeling abnormal—Travoprost—glaucoma	9.52e-05	0.000286	CcSEcCtD
Bortezomib—Conjunctivitis—Timolol—glaucoma	9.49e-05	0.000285	CcSEcCtD
Bortezomib—Gastrointestinal pain—Dorzolamide—glaucoma	9.49e-05	0.000285	CcSEcCtD
Bortezomib—Palpitations—Clonidine—glaucoma	9.48e-05	0.000285	CcSEcCtD
Bortezomib—Gastrointestinal disorder—Pilocarpine—glaucoma	9.47e-05	0.000285	CcSEcCtD
Bortezomib—Gastrointestinal pain—Travoprost—glaucoma	9.45e-05	0.000284	CcSEcCtD
Bortezomib—Loss of consciousness—Clonidine—glaucoma	9.43e-05	0.000284	CcSEcCtD
Bortezomib—Feeling abnormal—Brinzolamide—glaucoma	9.4e-05	0.000283	CcSEcCtD
Bortezomib—Mental disorder—Betaxolol—glaucoma	9.4e-05	0.000283	CcSEcCtD
Bortezomib—Constipation—Pilocarpine—glaucoma	9.38e-05	0.000282	CcSEcCtD
Bortezomib—Pain—Pilocarpine—glaucoma	9.38e-05	0.000282	CcSEcCtD
Bortezomib—Cough—Clonidine—glaucoma	9.36e-05	0.000282	CcSEcCtD
Bortezomib—Dizziness—Apraclonidine—glaucoma	9.36e-05	0.000281	CcSEcCtD
Bortezomib—Erythema—Betaxolol—glaucoma	9.34e-05	0.000281	CcSEcCtD
Bortezomib—Malnutrition—Betaxolol—glaucoma	9.34e-05	0.000281	CcSEcCtD
Bortezomib—Urticaria—Dorzolamide—glaucoma	9.22e-05	0.000277	CcSEcCtD
Bortezomib—Epistaxis—Timolol—glaucoma	9.21e-05	0.000277	CcSEcCtD
Bortezomib—Abdominal pain—Dorzolamide—glaucoma	9.17e-05	0.000276	CcSEcCtD
Bortezomib—Body temperature increased—Dorzolamide—glaucoma	9.17e-05	0.000276	CcSEcCtD
Bortezomib—Sinusitis—Timolol—glaucoma	9.16e-05	0.000276	CcSEcCtD
Bortezomib—Dysgeusia—Betaxolol—glaucoma	9.15e-05	0.000275	CcSEcCtD
Bortezomib—Arthralgia—Clonidine—glaucoma	9.13e-05	0.000275	CcSEcCtD
Bortezomib—Chest pain—Clonidine—glaucoma	9.13e-05	0.000275	CcSEcCtD
Bortezomib—Abdominal pain—Travoprost—glaucoma	9.13e-05	0.000275	CcSEcCtD
Bortezomib—Anxiety—Clonidine—glaucoma	9.1e-05	0.000274	CcSEcCtD
Bortezomib—Asthenia—Acetazolamide—glaucoma	9.08e-05	0.000273	CcSEcCtD
Bortezomib—Dizziness—Bimatoprost—glaucoma	9.07e-05	0.000273	CcSEcCtD
Bortezomib—Unspecified disorder of skin and subcutaneous tissue—Clonidine—glaucoma	9.07e-05	0.000273	CcSEcCtD
Bortezomib—Urticaria—Brinzolamide—glaucoma	9.06e-05	0.000273	CcSEcCtD
Bortezomib—Feeling abnormal—Pilocarpine—glaucoma	9.04e-05	0.000272	CcSEcCtD
Bortezomib—Discomfort—Clonidine—glaucoma	9.02e-05	0.000271	CcSEcCtD
Bortezomib—Vomiting—Apraclonidine—glaucoma	9e-05	0.000271	CcSEcCtD
Bortezomib—Muscle spasms—Betaxolol—glaucoma	8.98e-05	0.00027	CcSEcCtD
Bortezomib—Gastrointestinal pain—Pilocarpine—glaucoma	8.97e-05	0.00027	CcSEcCtD
Bortezomib—Hypersensitivity—Brimonidine—glaucoma	8.95e-05	0.000269	CcSEcCtD
Bortezomib—Bradycardia—Timolol—glaucoma	8.92e-05	0.000268	CcSEcCtD
Bortezomib—Dermatitis—Apraclonidine—glaucoma	8.92e-05	0.000268	CcSEcCtD
Bortezomib—Headache—Apraclonidine—glaucoma	8.87e-05	0.000267	CcSEcCtD
Bortezomib—Confusional state—Clonidine—glaucoma	8.83e-05	0.000266	CcSEcCtD
Bortezomib—Vision blurred—Betaxolol—glaucoma	8.8e-05	0.000265	CcSEcCtD
Bortezomib—Oedema—Clonidine—glaucoma	8.76e-05	0.000263	CcSEcCtD
Bortezomib—Tremor—Betaxolol—glaucoma	8.75e-05	0.000263	CcSEcCtD
Bortezomib—Hallucination—Timolol—glaucoma	8.72e-05	0.000262	CcSEcCtD
Bortezomib—Asthenia—Brimonidine—glaucoma	8.72e-05	0.000262	CcSEcCtD
Bortezomib—Infection—Clonidine—glaucoma	8.7e-05	0.000262	CcSEcCtD
Bortezomib—Abdominal pain—Pilocarpine—glaucoma	8.67e-05	0.000261	CcSEcCtD
Bortezomib—Body temperature increased—Pilocarpine—glaucoma	8.67e-05	0.000261	CcSEcCtD
Bortezomib—Ill-defined disorder—Betaxolol—glaucoma	8.67e-05	0.000261	CcSEcCtD
Bortezomib—Diarrhoea—Acetazolamide—glaucoma	8.66e-05	0.000261	CcSEcCtD
Bortezomib—Rash—Bimatoprost—glaucoma	8.65e-05	0.00026	CcSEcCtD
Bortezomib—Dermatitis—Bimatoprost—glaucoma	8.64e-05	0.00026	CcSEcCtD
Bortezomib—Oedema peripheral—Timolol—glaucoma	8.64e-05	0.00026	CcSEcCtD
Bortezomib—Anaemia—Betaxolol—glaucoma	8.63e-05	0.00026	CcSEcCtD
Bortezomib—Shock—Clonidine—glaucoma	8.61e-05	0.000259	CcSEcCtD
Bortezomib—Connective tissue disorder—Timolol—glaucoma	8.61e-05	0.000259	CcSEcCtD
Bortezomib—Pruritus—Brimonidine—glaucoma	8.6e-05	0.000259	CcSEcCtD
Bortezomib—Headache—Bimatoprost—glaucoma	8.6e-05	0.000259	CcSEcCtD
Bortezomib—Nervous system disorder—Clonidine—glaucoma	8.59e-05	0.000258	CcSEcCtD
Bortezomib—Thrombocytopenia—Clonidine—glaucoma	8.57e-05	0.000258	CcSEcCtD
Bortezomib—Hypersensitivity—Dorzolamide—glaucoma	8.55e-05	0.000257	CcSEcCtD
Bortezomib—Tachycardia—Clonidine—glaucoma	8.55e-05	0.000257	CcSEcCtD
Bortezomib—Hypersensitivity—Travoprost—glaucoma	8.51e-05	0.000256	CcSEcCtD
Bortezomib—Skin disorder—Clonidine—glaucoma	8.51e-05	0.000256	CcSEcCtD
Bortezomib—Hyperhidrosis—Clonidine—glaucoma	8.47e-05	0.000255	CcSEcCtD
Bortezomib—Visual impairment—Timolol—glaucoma	8.45e-05	0.000254	CcSEcCtD
Bortezomib—Malaise—Betaxolol—glaucoma	8.42e-05	0.000253	CcSEcCtD
Bortezomib—Nausea—Apraclonidine—glaucoma	8.41e-05	0.000253	CcSEcCtD
Bortezomib—Hypersensitivity—Brinzolamide—glaucoma	8.41e-05	0.000253	CcSEcCtD
Bortezomib—Vertigo—Betaxolol—glaucoma	8.39e-05	0.000252	CcSEcCtD
Bortezomib—Syncope—Betaxolol—glaucoma	8.38e-05	0.000252	CcSEcCtD
Bortezomib—Dizziness—Acetazolamide—glaucoma	8.37e-05	0.000252	CcSEcCtD
Bortezomib—Anorexia—Clonidine—glaucoma	8.35e-05	0.000251	CcSEcCtD
Bortezomib—Asthenia—Dorzolamide—glaucoma	8.33e-05	0.00025	CcSEcCtD
Bortezomib—Asthenia—Travoprost—glaucoma	8.29e-05	0.000249	CcSEcCtD
Bortezomib—Palpitations—Betaxolol—glaucoma	8.25e-05	0.000248	CcSEcCtD
Bortezomib—Pruritus—Dorzolamide—glaucoma	8.21e-05	0.000247	CcSEcCtD
Bortezomib—Loss of consciousness—Betaxolol—glaucoma	8.21e-05	0.000247	CcSEcCtD
Bortezomib—Eye disorder—Timolol—glaucoma	8.19e-05	0.000246	CcSEcCtD
Bortezomib—Asthenia—Brinzolamide—glaucoma	8.19e-05	0.000246	CcSEcCtD
Bortezomib—Hypotension—Clonidine—glaucoma	8.18e-05	0.000246	CcSEcCtD
Bortezomib—Pruritus—Travoprost—glaucoma	8.17e-05	0.000246	CcSEcCtD
Bortezomib—Tinnitus—Timolol—glaucoma	8.17e-05	0.000246	CcSEcCtD
Bortezomib—Cough—Betaxolol—glaucoma	8.15e-05	0.000245	CcSEcCtD
Bortezomib—Nausea—Bimatoprost—glaucoma	8.15e-05	0.000245	CcSEcCtD
Bortezomib—Cardiac disorder—Timolol—glaucoma	8.14e-05	0.000245	CcSEcCtD
Bortezomib—Hypersensitivity—Pilocarpine—glaucoma	8.08e-05	0.000243	CcSEcCtD
Bortezomib—Pruritus—Brinzolamide—glaucoma	8.07e-05	0.000243	CcSEcCtD
Bortezomib—Vomiting—Acetazolamide—glaucoma	8.05e-05	0.000242	CcSEcCtD
Bortezomib—Dizziness—Brimonidine—glaucoma	8.04e-05	0.000242	CcSEcCtD
Bortezomib—Musculoskeletal discomfort—Clonidine—glaucoma	7.98e-05	0.00024	CcSEcCtD
Bortezomib—Angiopathy—Timolol—glaucoma	7.95e-05	0.000239	CcSEcCtD
Bortezomib—Arthralgia—Betaxolol—glaucoma	7.95e-05	0.000239	CcSEcCtD
Bortezomib—Chest pain—Betaxolol—glaucoma	7.95e-05	0.000239	CcSEcCtD
Bortezomib—Myalgia—Betaxolol—glaucoma	7.95e-05	0.000239	CcSEcCtD
Bortezomib—Diarrhoea—Dorzolamide—glaucoma	7.94e-05	0.000239	CcSEcCtD
Bortezomib—Headache—Acetazolamide—glaucoma	7.93e-05	0.000239	CcSEcCtD
Bortezomib—Anxiety—Betaxolol—glaucoma	7.92e-05	0.000238	CcSEcCtD
Bortezomib—Insomnia—Clonidine—glaucoma	7.92e-05	0.000238	CcSEcCtD
Bortezomib—Immune system disorder—Timolol—glaucoma	7.92e-05	0.000238	CcSEcCtD
Bortezomib—Diarrhoea—Travoprost—glaucoma	7.91e-05	0.000238	CcSEcCtD
Bortezomib—Mediastinal disorder—Timolol—glaucoma	7.9e-05	0.000238	CcSEcCtD
Bortezomib—Unspecified disorder of skin and subcutaneous tissue—Betaxolol—glaucoma	7.9e-05	0.000238	CcSEcCtD
Bortezomib—Asthenia—Pilocarpine—glaucoma	7.87e-05	0.000237	CcSEcCtD
Bortezomib—Paraesthesia—Clonidine—glaucoma	7.86e-05	0.000236	CcSEcCtD
Bortezomib—Discomfort—Betaxolol—glaucoma	7.86e-05	0.000236	CcSEcCtD
Bortezomib—Arrhythmia—Timolol—glaucoma	7.83e-05	0.000236	CcSEcCtD
Bortezomib—Dyspnoea—Clonidine—glaucoma	7.81e-05	0.000235	CcSEcCtD
Bortezomib—Diarrhoea—Brinzolamide—glaucoma	7.81e-05	0.000235	CcSEcCtD
Bortezomib—Pruritus—Pilocarpine—glaucoma	7.76e-05	0.000233	CcSEcCtD
Bortezomib—Confusional state—Betaxolol—glaucoma	7.69e-05	0.000231	CcSEcCtD
Bortezomib—Mental disorder—Timolol—glaucoma	7.68e-05	0.000231	CcSEcCtD
Bortezomib—Dizziness—Dorzolamide—glaucoma	7.67e-05	0.000231	CcSEcCtD
Bortezomib—Rash—Brimonidine—glaucoma	7.66e-05	0.00023	CcSEcCtD
Bortezomib—Dermatitis—Brimonidine—glaucoma	7.65e-05	0.00023	CcSEcCtD
Bortezomib—Dizziness—Travoprost—glaucoma	7.64e-05	0.00023	CcSEcCtD
Bortezomib—Erythema—Timolol—glaucoma	7.63e-05	0.00023	CcSEcCtD
Bortezomib—Malnutrition—Timolol—glaucoma	7.63e-05	0.00023	CcSEcCtD
Bortezomib—Oedema—Betaxolol—glaucoma	7.62e-05	0.000229	CcSEcCtD
Bortezomib—Headache—Brimonidine—glaucoma	7.61e-05	0.000229	CcSEcCtD
Bortezomib—Decreased appetite—Clonidine—glaucoma	7.61e-05	0.000229	CcSEcCtD
Bortezomib—Infection—Betaxolol—glaucoma	7.57e-05	0.000228	CcSEcCtD
Bortezomib—Gastrointestinal disorder—Clonidine—glaucoma	7.56e-05	0.000227	CcSEcCtD
Bortezomib—Fatigue—Clonidine—glaucoma	7.55e-05	0.000227	CcSEcCtD
Bortezomib—Dizziness—Brinzolamide—glaucoma	7.54e-05	0.000227	CcSEcCtD
Bortezomib—Nausea—Acetazolamide—glaucoma	7.52e-05	0.000226	CcSEcCtD
Bortezomib—Diarrhoea—Pilocarpine—glaucoma	7.5e-05	0.000226	CcSEcCtD
Bortezomib—Shock—Betaxolol—glaucoma	7.5e-05	0.000226	CcSEcCtD
Bortezomib—Constipation—Clonidine—glaucoma	7.49e-05	0.000225	CcSEcCtD
Bortezomib—Pain—Clonidine—glaucoma	7.49e-05	0.000225	CcSEcCtD
Bortezomib—Nervous system disorder—Betaxolol—glaucoma	7.48e-05	0.000225	CcSEcCtD
Bortezomib—Dysgeusia—Timolol—glaucoma	7.47e-05	0.000225	CcSEcCtD
Bortezomib—Thrombocytopenia—Betaxolol—glaucoma	7.46e-05	0.000224	CcSEcCtD
Bortezomib—Tachycardia—Betaxolol—glaucoma	7.44e-05	0.000224	CcSEcCtD
Bortezomib—Skin disorder—Betaxolol—glaucoma	7.4e-05	0.000223	CcSEcCtD
Bortezomib—Vomiting—Dorzolamide—glaucoma	7.38e-05	0.000222	CcSEcCtD
Bortezomib—Hyperhidrosis—Betaxolol—glaucoma	7.37e-05	0.000222	CcSEcCtD
Bortezomib—Rash—Dorzolamide—glaucoma	7.32e-05	0.00022	CcSEcCtD
Bortezomib—Dermatitis—Dorzolamide—glaucoma	7.31e-05	0.00022	CcSEcCtD
Bortezomib—Rash—Travoprost—glaucoma	7.29e-05	0.000219	CcSEcCtD
Bortezomib—Dermatitis—Travoprost—glaucoma	7.28e-05	0.000219	CcSEcCtD
Bortezomib—Headache—Dorzolamide—glaucoma	7.27e-05	0.000219	CcSEcCtD
Bortezomib—Anorexia—Betaxolol—glaucoma	7.27e-05	0.000219	CcSEcCtD
Bortezomib—Vomiting—Brinzolamide—glaucoma	7.25e-05	0.000218	CcSEcCtD
Bortezomib—Dizziness—Pilocarpine—glaucoma	7.25e-05	0.000218	CcSEcCtD
Bortezomib—Headache—Travoprost—glaucoma	7.24e-05	0.000218	CcSEcCtD
Bortezomib—Nausea—Brimonidine—glaucoma	7.22e-05	0.000217	CcSEcCtD
Bortezomib—Feeling abnormal—Clonidine—glaucoma	7.22e-05	0.000217	CcSEcCtD
Bortezomib—Rash—Brinzolamide—glaucoma	7.19e-05	0.000216	CcSEcCtD
Bortezomib—Vision blurred—Timolol—glaucoma	7.19e-05	0.000216	CcSEcCtD
Bortezomib—Dermatitis—Brinzolamide—glaucoma	7.19e-05	0.000216	CcSEcCtD
Bortezomib—Gastrointestinal pain—Clonidine—glaucoma	7.16e-05	0.000215	CcSEcCtD
Bortezomib—Headache—Brinzolamide—glaucoma	7.15e-05	0.000215	CcSEcCtD
Bortezomib—Hypotension—Betaxolol—glaucoma	7.12e-05	0.000214	CcSEcCtD
Bortezomib—Angioedema—Timolol—glaucoma	6.97e-05	0.00021	CcSEcCtD
Bortezomib—Vomiting—Pilocarpine—glaucoma	6.97e-05	0.00021	CcSEcCtD
Bortezomib—Urticaria—Clonidine—glaucoma	6.96e-05	0.000209	CcSEcCtD
Bortezomib—Musculoskeletal discomfort—Betaxolol—glaucoma	6.95e-05	0.000209	CcSEcCtD
Bortezomib—Abdominal pain—Clonidine—glaucoma	6.92e-05	0.000208	CcSEcCtD
Bortezomib—Body temperature increased—Clonidine—glaucoma	6.92e-05	0.000208	CcSEcCtD
Bortezomib—Rash—Pilocarpine—glaucoma	6.91e-05	0.000208	CcSEcCtD
Bortezomib—Dermatitis—Pilocarpine—glaucoma	6.91e-05	0.000208	CcSEcCtD
Bortezomib—Insomnia—Betaxolol—glaucoma	6.9e-05	0.000207	CcSEcCtD
Bortezomib—Nausea—Dorzolamide—glaucoma	6.89e-05	0.000207	CcSEcCtD
Bortezomib—Headache—Pilocarpine—glaucoma	6.87e-05	0.000207	CcSEcCtD
Bortezomib—Nausea—Travoprost—glaucoma	6.86e-05	0.000206	CcSEcCtD
Bortezomib—Vertigo—Timolol—glaucoma	6.86e-05	0.000206	CcSEcCtD
Bortezomib—Paraesthesia—Betaxolol—glaucoma	6.85e-05	0.000206	CcSEcCtD
Bortezomib—Syncope—Timolol—glaucoma	6.84e-05	0.000206	CcSEcCtD
Bortezomib—Dyspnoea—Betaxolol—glaucoma	6.8e-05	0.000204	CcSEcCtD
Bortezomib—Nausea—Brinzolamide—glaucoma	6.78e-05	0.000204	CcSEcCtD
Bortezomib—Palpitations—Timolol—glaucoma	6.74e-05	0.000203	CcSEcCtD
Bortezomib—Dyspepsia—Betaxolol—glaucoma	6.71e-05	0.000202	CcSEcCtD
Bortezomib—Loss of consciousness—Timolol—glaucoma	6.71e-05	0.000202	CcSEcCtD
Bortezomib—Cough—Timolol—glaucoma	6.66e-05	0.0002	CcSEcCtD
Bortezomib—Decreased appetite—Betaxolol—glaucoma	6.63e-05	0.000199	CcSEcCtD
Bortezomib—Hypertension—Timolol—glaucoma	6.59e-05	0.000198	CcSEcCtD
Bortezomib—Gastrointestinal disorder—Betaxolol—glaucoma	6.58e-05	0.000198	CcSEcCtD
Bortezomib—Fatigue—Betaxolol—glaucoma	6.57e-05	0.000198	CcSEcCtD
Bortezomib—Pain—Betaxolol—glaucoma	6.52e-05	0.000196	CcSEcCtD
Bortezomib—Constipation—Betaxolol—glaucoma	6.52e-05	0.000196	CcSEcCtD
Bortezomib—Nausea—Pilocarpine—glaucoma	6.51e-05	0.000196	CcSEcCtD
Bortezomib—Chest pain—Timolol—glaucoma	6.5e-05	0.000195	CcSEcCtD
Bortezomib—Myalgia—Timolol—glaucoma	6.5e-05	0.000195	CcSEcCtD
Bortezomib—Arthralgia—Timolol—glaucoma	6.5e-05	0.000195	CcSEcCtD
Bortezomib—Anxiety—Timolol—glaucoma	6.47e-05	0.000195	CcSEcCtD
Bortezomib—Unspecified disorder of skin and subcutaneous tissue—Timolol—glaucoma	6.45e-05	0.000194	CcSEcCtD
Bortezomib—Hypersensitivity—Clonidine—glaucoma	6.45e-05	0.000194	CcSEcCtD
Bortezomib—Discomfort—Timolol—glaucoma	6.42e-05	0.000193	CcSEcCtD
Bortezomib—Asthenia—Clonidine—glaucoma	6.28e-05	0.000189	CcSEcCtD
Bortezomib—Feeling abnormal—Betaxolol—glaucoma	6.28e-05	0.000189	CcSEcCtD
Bortezomib—Confusional state—Timolol—glaucoma	6.28e-05	0.000189	CcSEcCtD
Bortezomib—Anaphylactic shock—Timolol—glaucoma	6.23e-05	0.000187	CcSEcCtD
Bortezomib—Oedema—Timolol—glaucoma	6.23e-05	0.000187	CcSEcCtD
Bortezomib—Pruritus—Clonidine—glaucoma	6.2e-05	0.000186	CcSEcCtD
Bortezomib—Infection—Timolol—glaucoma	6.19e-05	0.000186	CcSEcCtD
Bortezomib—Shock—Timolol—glaucoma	6.13e-05	0.000184	CcSEcCtD
Bortezomib—Nervous system disorder—Timolol—glaucoma	6.11e-05	0.000184	CcSEcCtD
Bortezomib—Urticaria—Betaxolol—glaucoma	6.06e-05	0.000182	CcSEcCtD
Bortezomib—Skin disorder—Timolol—glaucoma	6.05e-05	0.000182	CcSEcCtD
Bortezomib—Body temperature increased—Betaxolol—glaucoma	6.03e-05	0.000181	CcSEcCtD
Bortezomib—Hyperhidrosis—Timolol—glaucoma	6.02e-05	0.000181	CcSEcCtD
Bortezomib—Diarrhoea—Clonidine—glaucoma	5.99e-05	0.00018	CcSEcCtD
Bortezomib—Anorexia—Timolol—glaucoma	5.94e-05	0.000179	CcSEcCtD
Bortezomib—Hypotension—Timolol—glaucoma	5.82e-05	0.000175	CcSEcCtD
Bortezomib—Dizziness—Clonidine—glaucoma	5.79e-05	0.000174	CcSEcCtD
Bortezomib—Musculoskeletal discomfort—Timolol—glaucoma	5.67e-05	0.000171	CcSEcCtD
Bortezomib—Insomnia—Timolol—glaucoma	5.63e-05	0.000169	CcSEcCtD
Bortezomib—Hypersensitivity—Betaxolol—glaucoma	5.62e-05	0.000169	CcSEcCtD
Bortezomib—Paraesthesia—Timolol—glaucoma	5.59e-05	0.000168	CcSEcCtD
Bortezomib—Vomiting—Clonidine—glaucoma	5.57e-05	0.000167	CcSEcCtD
Bortezomib—Dyspnoea—Timolol—glaucoma	5.55e-05	0.000167	CcSEcCtD
Bortezomib—Rash—Clonidine—glaucoma	5.52e-05	0.000166	CcSEcCtD
Bortezomib—Dermatitis—Clonidine—glaucoma	5.52e-05	0.000166	CcSEcCtD
Bortezomib—Headache—Clonidine—glaucoma	5.49e-05	0.000165	CcSEcCtD
Bortezomib—Dyspepsia—Timolol—glaucoma	5.48e-05	0.000165	CcSEcCtD
Bortezomib—Asthenia—Betaxolol—glaucoma	5.47e-05	0.000165	CcSEcCtD
Bortezomib—Decreased appetite—Timolol—glaucoma	5.41e-05	0.000163	CcSEcCtD
Bortezomib—Pruritus—Betaxolol—glaucoma	5.39e-05	0.000162	CcSEcCtD
Bortezomib—Gastrointestinal disorder—Timolol—glaucoma	5.38e-05	0.000162	CcSEcCtD
Bortezomib—Fatigue—Timolol—glaucoma	5.37e-05	0.000161	CcSEcCtD
Bortezomib—Pain—Timolol—glaucoma	5.33e-05	0.00016	CcSEcCtD
Bortezomib—Diarrhoea—Betaxolol—glaucoma	5.22e-05	0.000157	CcSEcCtD
Bortezomib—Nausea—Clonidine—glaucoma	5.2e-05	0.000156	CcSEcCtD
Bortezomib—Feeling abnormal—Timolol—glaucoma	5.13e-05	0.000154	CcSEcCtD
Bortezomib—Gastrointestinal pain—Timolol—glaucoma	5.09e-05	0.000153	CcSEcCtD
Bortezomib—Dizziness—Betaxolol—glaucoma	5.04e-05	0.000152	CcSEcCtD
Bortezomib—Urticaria—Timolol—glaucoma	4.95e-05	0.000149	CcSEcCtD
Bortezomib—Body temperature increased—Timolol—glaucoma	4.92e-05	0.000148	CcSEcCtD
Bortezomib—Abdominal pain—Timolol—glaucoma	4.92e-05	0.000148	CcSEcCtD
Bortezomib—Vomiting—Betaxolol—glaucoma	4.85e-05	0.000146	CcSEcCtD
Bortezomib—Rash—Betaxolol—glaucoma	4.81e-05	0.000145	CcSEcCtD
Bortezomib—Dermatitis—Betaxolol—glaucoma	4.8e-05	0.000144	CcSEcCtD
Bortezomib—Headache—Betaxolol—glaucoma	4.78e-05	0.000144	CcSEcCtD
Bortezomib—Hypersensitivity—Timolol—glaucoma	4.59e-05	0.000138	CcSEcCtD
Bortezomib—Nausea—Betaxolol—glaucoma	4.53e-05	0.000136	CcSEcCtD
Bortezomib—Asthenia—Timolol—glaucoma	4.47e-05	0.000134	CcSEcCtD
Bortezomib—Pruritus—Timolol—glaucoma	4.41e-05	0.000133	CcSEcCtD
Bortezomib—Diarrhoea—Timolol—glaucoma	4.26e-05	0.000128	CcSEcCtD
Bortezomib—Dizziness—Timolol—glaucoma	4.12e-05	0.000124	CcSEcCtD
Bortezomib—Vomiting—Timolol—glaucoma	3.96e-05	0.000119	CcSEcCtD
Bortezomib—Rash—Timolol—glaucoma	3.93e-05	0.000118	CcSEcCtD
Bortezomib—Dermatitis—Timolol—glaucoma	3.92e-05	0.000118	CcSEcCtD
Bortezomib—Headache—Timolol—glaucoma	3.9e-05	0.000117	CcSEcCtD
Bortezomib—Nausea—Timolol—glaucoma	3.7e-05	0.000111	CcSEcCtD
Bortezomib—PSMB2—Disease—BAD—glaucoma	2.15e-05	0.000133	CbGpPWpGaD
Bortezomib—PSMA1—Immune System—CDKN1B—glaucoma	2.14e-05	0.000133	CbGpPWpGaD
Bortezomib—PSMA1—Signaling Pathways—APOE—glaucoma	2.13e-05	0.000132	CbGpPWpGaD
Bortezomib—PSMD1—Immune System—CDKN1B—glaucoma	2.13e-05	0.000132	CbGpPWpGaD
Bortezomib—PSMD1—Signaling Pathways—APOE—glaucoma	2.12e-05	0.000131	CbGpPWpGaD
Bortezomib—PSMB8—Disease—BAD—glaucoma	2.12e-05	0.000131	CbGpPWpGaD
Bortezomib—PSMD2—Immune System—CDKN1B—glaucoma	2.12e-05	0.000131	CbGpPWpGaD
Bortezomib—PSMA1—Signaling Pathways—CAV1—glaucoma	2.11e-05	0.000131	CbGpPWpGaD
Bortezomib—PSMD2—Signaling Pathways—APOE—glaucoma	2.11e-05	0.000131	CbGpPWpGaD
Bortezomib—PSMD1—Signaling Pathways—CAV1—glaucoma	2.1e-05	0.00013	CbGpPWpGaD
Bortezomib—PSMD2—Signaling Pathways—CAV1—glaucoma	2.09e-05	0.00013	CbGpPWpGaD
Bortezomib—PSMA1—Disease—PTGS2—glaucoma	2.08e-05	0.000129	CbGpPWpGaD
Bortezomib—PSMD1—Disease—PTGS2—glaucoma	2.07e-05	0.000129	CbGpPWpGaD
Bortezomib—PSMB5—Metabolism—MTHFR—glaucoma	2.07e-05	0.000129	CbGpPWpGaD
Bortezomib—PSMB1—Metabolism—MTHFR—glaucoma	2.07e-05	0.000129	CbGpPWpGaD
Bortezomib—PSMB2—Metabolism—MTHFR—glaucoma	2.07e-05	0.000129	CbGpPWpGaD
Bortezomib—PSMB5—Signaling Pathways—CDKN2B—glaucoma	2.07e-05	0.000128	CbGpPWpGaD
Bortezomib—PSMB1—Signaling Pathways—CDKN2B—glaucoma	2.07e-05	0.000128	CbGpPWpGaD
Bortezomib—PSMB2—Signaling Pathways—CDKN2B—glaucoma	2.07e-05	0.000128	CbGpPWpGaD
Bortezomib—PSMD2—Disease—PTGS2—glaucoma	2.06e-05	0.000128	CbGpPWpGaD
Bortezomib—PSMB8—Metabolism—MTHFR—glaucoma	2.04e-05	0.000127	CbGpPWpGaD
Bortezomib—CYP2D6—Metabolism—CA1—glaucoma	2.04e-05	0.000127	CbGpPWpGaD
Bortezomib—PSMB8—Signaling Pathways—CDKN2B—glaucoma	2.04e-05	0.000126	CbGpPWpGaD
Bortezomib—CYP2C19—Metabolism—CA2—glaucoma	2.03e-05	0.000126	CbGpPWpGaD
Bortezomib—CYP2C9—Metabolism—CA1—glaucoma	2.03e-05	0.000126	CbGpPWpGaD
Bortezomib—PSMA1—Signaling Pathways—FN1—glaucoma	2.01e-05	0.000125	CbGpPWpGaD
Bortezomib—PSMD1—Signaling Pathways—FN1—glaucoma	2e-05	0.000124	CbGpPWpGaD
Bortezomib—PSMD2—Signaling Pathways—FN1—glaucoma	1.99e-05	0.000123	CbGpPWpGaD
Bortezomib—CYP2C19—Metabolism of lipids and lipoproteins—ABCA1—glaucoma	1.99e-05	0.000123	CbGpPWpGaD
Bortezomib—CYP2C19—Metabolism of lipids and lipoproteins—CYP1B1—glaucoma	1.99e-05	0.000123	CbGpPWpGaD
Bortezomib—PSMB1—Signaling Pathways—EDN1—glaucoma	1.98e-05	0.000123	CbGpPWpGaD
Bortezomib—PSMA1—Signaling Pathways—BAD—glaucoma	1.98e-05	0.000123	CbGpPWpGaD
Bortezomib—PSMB5—Signaling Pathways—EDN1—glaucoma	1.98e-05	0.000123	CbGpPWpGaD
Bortezomib—PSMB2—Signaling Pathways—EDN1—glaucoma	1.98e-05	0.000123	CbGpPWpGaD
Bortezomib—CYP2D6—Metabolism—CTSA—glaucoma	1.98e-05	0.000123	CbGpPWpGaD
Bortezomib—PSMD1—Signaling Pathways—BAD—glaucoma	1.97e-05	0.000122	CbGpPWpGaD
Bortezomib—PSMA1—Disease—CDKN1B—glaucoma	1.97e-05	0.000122	CbGpPWpGaD
Bortezomib—PSMD2—Signaling Pathways—BAD—glaucoma	1.97e-05	0.000122	CbGpPWpGaD
Bortezomib—PSMD1—Disease—CDKN1B—glaucoma	1.96e-05	0.000122	CbGpPWpGaD
Bortezomib—CYP2C9—Metabolism—CTSA—glaucoma	1.96e-05	0.000122	CbGpPWpGaD
Bortezomib—PSMB8—Signaling Pathways—EDN1—glaucoma	1.96e-05	0.000121	CbGpPWpGaD
Bortezomib—PSMD2—Disease—CDKN1B—glaucoma	1.95e-05	0.000121	CbGpPWpGaD
Bortezomib—PSMB2—Metabolism—APOE—glaucoma	1.93e-05	0.00012	CbGpPWpGaD
Bortezomib—PSMB1—Metabolism—APOE—glaucoma	1.93e-05	0.00012	CbGpPWpGaD
Bortezomib—PSMB5—Metabolism—APOE—glaucoma	1.93e-05	0.00012	CbGpPWpGaD
Bortezomib—PTGS1—Metabolism—GSTT1—glaucoma	1.93e-05	0.000119	CbGpPWpGaD
Bortezomib—PSMB5—Metabolism—CAV1—glaucoma	1.91e-05	0.000119	CbGpPWpGaD
Bortezomib—PSMB1—Metabolism—CAV1—glaucoma	1.91e-05	0.000119	CbGpPWpGaD
Bortezomib—PSMB2—Metabolism—CAV1—glaucoma	1.91e-05	0.000119	CbGpPWpGaD
Bortezomib—PSMA1—Metabolism—NOS3—glaucoma	1.91e-05	0.000118	CbGpPWpGaD
Bortezomib—PSMB8—Metabolism—APOE—glaucoma	1.9e-05	0.000118	CbGpPWpGaD
Bortezomib—PSMD1—Metabolism—NOS3—glaucoma	1.9e-05	0.000118	CbGpPWpGaD
Bortezomib—PSMD2—Metabolism—NOS3—glaucoma	1.89e-05	0.000117	CbGpPWpGaD
Bortezomib—PSMB8—Metabolism—CAV1—glaucoma	1.89e-05	0.000117	CbGpPWpGaD
Bortezomib—CYP2D6—Metabolism—CA2—glaucoma	1.87e-05	0.000116	CbGpPWpGaD
Bortezomib—CYP2C9—Metabolism—CA2—glaucoma	1.85e-05	0.000115	CbGpPWpGaD
Bortezomib—PSMB2—Cell Cycle—TP53—glaucoma	1.83e-05	0.000114	CbGpPWpGaD
Bortezomib—PSMB1—Cell Cycle—TP53—glaucoma	1.83e-05	0.000114	CbGpPWpGaD
Bortezomib—PSMB5—Cell Cycle—TP53—glaucoma	1.83e-05	0.000114	CbGpPWpGaD
Bortezomib—PSMB1—Signaling Pathways—NGF—glaucoma	1.82e-05	0.000113	CbGpPWpGaD
Bortezomib—PSMB5—Signaling Pathways—NGF—glaucoma	1.82e-05	0.000113	CbGpPWpGaD
Bortezomib—PSMB2—Signaling Pathways—NGF—glaucoma	1.82e-05	0.000113	CbGpPWpGaD
Bortezomib—CYP2C9—Metabolism of lipids and lipoproteins—CYP1B1—glaucoma	1.81e-05	0.000112	CbGpPWpGaD
Bortezomib—CYP2C9—Metabolism of lipids and lipoproteins—ABCA1—glaucoma	1.81e-05	0.000112	CbGpPWpGaD
Bortezomib—PSMB8—Cell Cycle—TP53—glaucoma	1.81e-05	0.000112	CbGpPWpGaD
Bortezomib—PSMB8—Signaling Pathways—NGF—glaucoma	1.8e-05	0.000111	CbGpPWpGaD
Bortezomib—CYP1A1—Metabolism—TXN—glaucoma	1.75e-05	0.000108	CbGpPWpGaD
Bortezomib—PSMA1—Metabolism—PTGS2—glaucoma	1.74e-05	0.000108	CbGpPWpGaD
Bortezomib—PSMD1—Metabolism—PTGS2—glaucoma	1.74e-05	0.000108	CbGpPWpGaD
Bortezomib—PSMB2—Signaling Pathways—C3—glaucoma	1.73e-05	0.000107	CbGpPWpGaD
Bortezomib—PSMB5—Signaling Pathways—C3—glaucoma	1.73e-05	0.000107	CbGpPWpGaD
Bortezomib—PSMB1—Signaling Pathways—C3—glaucoma	1.73e-05	0.000107	CbGpPWpGaD
Bortezomib—CYP1A2—Metabolism—CA1—glaucoma	1.73e-05	0.000107	CbGpPWpGaD
Bortezomib—PSMD2—Metabolism—PTGS2—glaucoma	1.73e-05	0.000107	CbGpPWpGaD
Bortezomib—PSMB5—Disease—NOS3—glaucoma	1.73e-05	0.000107	CbGpPWpGaD
Bortezomib—PSMB2—Disease—NOS3—glaucoma	1.73e-05	0.000107	CbGpPWpGaD
Bortezomib—PSMB1—Disease—NOS3—glaucoma	1.73e-05	0.000107	CbGpPWpGaD
Bortezomib—PSMB8—Signaling Pathways—C3—glaucoma	1.71e-05	0.000106	CbGpPWpGaD
Bortezomib—PSMB8—Disease—NOS3—glaucoma	1.7e-05	0.000106	CbGpPWpGaD
Bortezomib—CYP1A2—Metabolism—CTSA—glaucoma	1.68e-05	0.000104	CbGpPWpGaD
Bortezomib—PSMB2—Immune System—CDKN1B—glaucoma	1.62e-05	0.0001	CbGpPWpGaD
Bortezomib—PSMB5—Immune System—CDKN1B—glaucoma	1.62e-05	0.0001	CbGpPWpGaD
Bortezomib—PSMB1—Immune System—CDKN1B—glaucoma	1.62e-05	0.0001	CbGpPWpGaD
Bortezomib—PSMB2—Signaling Pathways—APOE—glaucoma	1.61e-05	0.0001	CbGpPWpGaD
Bortezomib—PSMB1—Signaling Pathways—APOE—glaucoma	1.61e-05	0.0001	CbGpPWpGaD
Bortezomib—PSMB5—Signaling Pathways—APOE—glaucoma	1.61e-05	0.0001	CbGpPWpGaD
Bortezomib—CYP2C8—Metabolism—TXN—glaucoma	1.6e-05	9.95e-05	CbGpPWpGaD
Bortezomib—PSMB5—Signaling Pathways—CAV1—glaucoma	1.6e-05	9.92e-05	CbGpPWpGaD
Bortezomib—PSMB1—Signaling Pathways—CAV1—glaucoma	1.6e-05	9.92e-05	CbGpPWpGaD
Bortezomib—PSMB2—Signaling Pathways—CAV1—glaucoma	1.6e-05	9.92e-05	CbGpPWpGaD
Bortezomib—PSMB8—Immune System—CDKN1B—glaucoma	1.6e-05	9.9e-05	CbGpPWpGaD
Bortezomib—CYP1A1—Metabolism of lipids and lipoproteins—APOE—glaucoma	1.6e-05	9.9e-05	CbGpPWpGaD
Bortezomib—PSMA1—Signaling Pathways—NOS3—glaucoma	1.6e-05	9.89e-05	CbGpPWpGaD
Bortezomib—PSMB8—Signaling Pathways—APOE—glaucoma	1.59e-05	9.87e-05	CbGpPWpGaD
Bortezomib—PSMD1—Signaling Pathways—NOS3—glaucoma	1.59e-05	9.85e-05	CbGpPWpGaD
Bortezomib—CYP1A2—Metabolism—CA2—glaucoma	1.58e-05	9.82e-05	CbGpPWpGaD
Bortezomib—CYP1A1—Metabolism of lipids and lipoproteins—CAV1—glaucoma	1.58e-05	9.81e-05	CbGpPWpGaD
Bortezomib—PSMD2—Signaling Pathways—NOS3—glaucoma	1.58e-05	9.8e-05	CbGpPWpGaD
Bortezomib—PSMB2—Disease—PTGS2—glaucoma	1.58e-05	9.79e-05	CbGpPWpGaD
Bortezomib—PSMB5—Disease—PTGS2—glaucoma	1.58e-05	9.79e-05	CbGpPWpGaD
Bortezomib—PSMB1—Disease—PTGS2—glaucoma	1.58e-05	9.79e-05	CbGpPWpGaD
Bortezomib—PSMB8—Signaling Pathways—CAV1—glaucoma	1.58e-05	9.78e-05	CbGpPWpGaD
Bortezomib—PSMB8—Disease—PTGS2—glaucoma	1.56e-05	9.65e-05	CbGpPWpGaD
Bortezomib—PTGS1—Metabolism of lipids and lipoproteins—PTGS2—glaucoma	1.55e-05	9.63e-05	CbGpPWpGaD
Bortezomib—CYP1A2—Metabolism of lipids and lipoproteins—ABCA1—glaucoma	1.55e-05	9.6e-05	CbGpPWpGaD
Bortezomib—CYP1A2—Metabolism of lipids and lipoproteins—CYP1B1—glaucoma	1.55e-05	9.6e-05	CbGpPWpGaD
Bortezomib—PTGS1—Metabolism—ABCA1—glaucoma	1.53e-05	9.51e-05	CbGpPWpGaD
Bortezomib—PTGS1—Metabolism—CYP1B1—glaucoma	1.53e-05	9.51e-05	CbGpPWpGaD
Bortezomib—PSMB5—Signaling Pathways—FN1—glaucoma	1.52e-05	9.44e-05	CbGpPWpGaD
Bortezomib—PSMB1—Signaling Pathways—FN1—glaucoma	1.52e-05	9.44e-05	CbGpPWpGaD
Bortezomib—PSMB2—Signaling Pathways—FN1—glaucoma	1.52e-05	9.44e-05	CbGpPWpGaD
Bortezomib—PSMB2—Signaling Pathways—BAD—glaucoma	1.5e-05	9.33e-05	CbGpPWpGaD
Bortezomib—PSMB5—Signaling Pathways—BAD—glaucoma	1.5e-05	9.33e-05	CbGpPWpGaD
Bortezomib—PSMB1—Signaling Pathways—BAD—glaucoma	1.5e-05	9.33e-05	CbGpPWpGaD
Bortezomib—PSMB8—Signaling Pathways—FN1—glaucoma	1.5e-05	9.3e-05	CbGpPWpGaD
Bortezomib—PSMB5—Disease—CDKN1B—glaucoma	1.5e-05	9.27e-05	CbGpPWpGaD
Bortezomib—PSMB1—Disease—CDKN1B—glaucoma	1.5e-05	9.27e-05	CbGpPWpGaD
Bortezomib—PSMB2—Disease—CDKN1B—glaucoma	1.5e-05	9.27e-05	CbGpPWpGaD
Bortezomib—PSMB8—Signaling Pathways—BAD—glaucoma	1.48e-05	9.19e-05	CbGpPWpGaD
Bortezomib—PSMB8—Disease—CDKN1B—glaucoma	1.47e-05	9.14e-05	CbGpPWpGaD
Bortezomib—CYP2C8—Metabolism of lipids and lipoproteins—APOE—glaucoma	1.46e-05	9.08e-05	CbGpPWpGaD
Bortezomib—CYP2C8—Metabolism of lipids and lipoproteins—CAV1—glaucoma	1.45e-05	8.99e-05	CbGpPWpGaD
Bortezomib—PSMB2—Metabolism—NOS3—glaucoma	1.45e-05	8.97e-05	CbGpPWpGaD
Bortezomib—PSMB1—Metabolism—NOS3—glaucoma	1.45e-05	8.97e-05	CbGpPWpGaD
Bortezomib—PSMB5—Metabolism—NOS3—glaucoma	1.45e-05	8.97e-05	CbGpPWpGaD
Bortezomib—CYP2C19—Metabolism—TXN—glaucoma	1.43e-05	8.88e-05	CbGpPWpGaD
Bortezomib—PSMB8—Metabolism—NOS3—glaucoma	1.43e-05	8.84e-05	CbGpPWpGaD
Bortezomib—PSMA1—Signaling Pathways—CDKN1B—glaucoma	1.38e-05	8.57e-05	CbGpPWpGaD
Bortezomib—PSMD1—Signaling Pathways—CDKN1B—glaucoma	1.38e-05	8.53e-05	CbGpPWpGaD
Bortezomib—PSMD2—Signaling Pathways—CDKN1B—glaucoma	1.37e-05	8.49e-05	CbGpPWpGaD
Bortezomib—CYP1A1—Metabolism—GSTT1—glaucoma	1.36e-05	8.41e-05	CbGpPWpGaD
Bortezomib—CYP3A4—Metabolism—CA1—glaucoma	1.34e-05	8.28e-05	CbGpPWpGaD
Bortezomib—PSMB1—Metabolism—PTGS2—glaucoma	1.32e-05	8.2e-05	CbGpPWpGaD
Bortezomib—PSMB5—Metabolism—PTGS2—glaucoma	1.32e-05	8.2e-05	CbGpPWpGaD
Bortezomib—PSMB2—Metabolism—PTGS2—glaucoma	1.32e-05	8.2e-05	CbGpPWpGaD
Bortezomib—CYP2D6—Metabolism—TXN—glaucoma	1.32e-05	8.17e-05	CbGpPWpGaD
Bortezomib—CYP2C19—Metabolism of lipids and lipoproteins—APOE—glaucoma	1.31e-05	8.1e-05	CbGpPWpGaD
Bortezomib—CYP2C9—Metabolism—TXN—glaucoma	1.31e-05	8.09e-05	CbGpPWpGaD
Bortezomib—PSMB8—Metabolism—PTGS2—glaucoma	1.3e-05	8.09e-05	CbGpPWpGaD
Bortezomib—CYP2C19—Metabolism of lipids and lipoproteins—CAV1—glaucoma	1.29e-05	8.03e-05	CbGpPWpGaD
Bortezomib—CYP3A4—Metabolism—CTSA—glaucoma	1.29e-05	8.02e-05	CbGpPWpGaD
Bortezomib—PSMA1—Signaling Pathways—MMP9—glaucoma	1.28e-05	7.94e-05	CbGpPWpGaD
Bortezomib—PSMD1—Signaling Pathways—MMP9—glaucoma	1.27e-05	7.9e-05	CbGpPWpGaD
Bortezomib—PSMD2—Signaling Pathways—MMP9—glaucoma	1.27e-05	7.86e-05	CbGpPWpGaD
Bortezomib—CYP2C8—Metabolism—GSTT1—glaucoma	1.24e-05	7.71e-05	CbGpPWpGaD
Bortezomib—PTGS1—Metabolism—GSTM1—glaucoma	1.23e-05	7.61e-05	CbGpPWpGaD
Bortezomib—CYP3A4—Metabolism—CA2—glaucoma	1.22e-05	7.58e-05	CbGpPWpGaD
Bortezomib—PSMB5—Signaling Pathways—NOS3—glaucoma	1.21e-05	7.5e-05	CbGpPWpGaD
Bortezomib—PSMB1—Signaling Pathways—NOS3—glaucoma	1.21e-05	7.5e-05	CbGpPWpGaD
Bortezomib—PSMB2—Signaling Pathways—NOS3—glaucoma	1.21e-05	7.5e-05	CbGpPWpGaD
Bortezomib—PSMB8—Signaling Pathways—NOS3—glaucoma	1.19e-05	7.39e-05	CbGpPWpGaD
Bortezomib—CYP2C9—Metabolism of lipids and lipoproteins—APOE—glaucoma	1.19e-05	7.39e-05	CbGpPWpGaD
Bortezomib—CYP2C9—Metabolism of lipids and lipoproteins—CAV1—glaucoma	1.18e-05	7.32e-05	CbGpPWpGaD
Bortezomib—PSMA1—Signaling Pathways—VEGFA—glaucoma	1.15e-05	7.13e-05	CbGpPWpGaD
Bortezomib—PSMD1—Signaling Pathways—VEGFA—glaucoma	1.14e-05	7.09e-05	CbGpPWpGaD
Bortezomib—PSMD2—Signaling Pathways—VEGFA—glaucoma	1.14e-05	7.06e-05	CbGpPWpGaD
Bortezomib—CYP1A2—Metabolism—TXN—glaucoma	1.12e-05	6.92e-05	CbGpPWpGaD
Bortezomib—CYP2C19—Metabolism—GSTT1—glaucoma	1.11e-05	6.88e-05	CbGpPWpGaD
Bortezomib—CYP1A1—Metabolism of lipids and lipoproteins—PTGS2—glaucoma	1.09e-05	6.78e-05	CbGpPWpGaD
Bortezomib—PTGS1—Metabolism—MTHFR—glaucoma	1.08e-05	6.72e-05	CbGpPWpGaD
Bortezomib—CYP1A1—Metabolism—CYP1B1—glaucoma	1.08e-05	6.7e-05	CbGpPWpGaD
Bortezomib—CYP1A1—Metabolism—ABCA1—glaucoma	1.08e-05	6.7e-05	CbGpPWpGaD
Bortezomib—PSMB1—Signaling Pathways—CDKN1B—glaucoma	1.05e-05	6.49e-05	CbGpPWpGaD
Bortezomib—PSMB5—Signaling Pathways—CDKN1B—glaucoma	1.05e-05	6.49e-05	CbGpPWpGaD
Bortezomib—PSMB2—Signaling Pathways—CDKN1B—glaucoma	1.05e-05	6.49e-05	CbGpPWpGaD
Bortezomib—PSMB8—Signaling Pathways—CDKN1B—glaucoma	1.03e-05	6.4e-05	CbGpPWpGaD
Bortezomib—CYP2D6—Metabolism—GSTT1—glaucoma	1.02e-05	6.33e-05	CbGpPWpGaD
Bortezomib—CYP1A2—Metabolism of lipids and lipoproteins—APOE—glaucoma	1.02e-05	6.31e-05	CbGpPWpGaD
Bortezomib—CYP2C9—Metabolism—GSTT1—glaucoma	1.01e-05	6.28e-05	CbGpPWpGaD
Bortezomib—PTGS1—Metabolism—APOE—glaucoma	1.01e-05	6.26e-05	CbGpPWpGaD
Bortezomib—CYP1A2—Metabolism of lipids and lipoproteins—CAV1—glaucoma	1.01e-05	6.25e-05	CbGpPWpGaD
Bortezomib—CYP2C8—Metabolism of lipids and lipoproteins—PTGS2—glaucoma	1e-05	6.22e-05	CbGpPWpGaD
Bortezomib—PTGS1—Metabolism—CAV1—glaucoma	1e-05	6.2e-05	CbGpPWpGaD
Bortezomib—CYP2C8—Metabolism—ABCA1—glaucoma	9.91e-06	6.14e-05	CbGpPWpGaD
Bortezomib—CYP2C8—Metabolism—CYP1B1—glaucoma	9.91e-06	6.14e-05	CbGpPWpGaD
Bortezomib—PSMB1—Signaling Pathways—MMP9—glaucoma	9.7e-06	6.02e-05	CbGpPWpGaD
Bortezomib—PSMB5—Signaling Pathways—MMP9—glaucoma	9.7e-06	6.02e-05	CbGpPWpGaD
Bortezomib—PSMB2—Signaling Pathways—MMP9—glaucoma	9.7e-06	6.02e-05	CbGpPWpGaD
Bortezomib—PSMB8—Signaling Pathways—MMP9—glaucoma	9.56e-06	5.93e-05	CbGpPWpGaD
Bortezomib—CYP2C19—Metabolism of lipids and lipoproteins—PTGS2—glaucoma	8.95e-06	5.55e-05	CbGpPWpGaD
Bortezomib—CYP2C19—Metabolism—ABCA1—glaucoma	8.84e-06	5.48e-05	CbGpPWpGaD
Bortezomib—CYP2C19—Metabolism—CYP1B1—glaucoma	8.84e-06	5.48e-05	CbGpPWpGaD
Bortezomib—PSMB5—Signaling Pathways—VEGFA—glaucoma	8.71e-06	5.4e-05	CbGpPWpGaD
Bortezomib—PSMB2—Signaling Pathways—VEGFA—glaucoma	8.71e-06	5.4e-05	CbGpPWpGaD
Bortezomib—PSMB1—Signaling Pathways—VEGFA—glaucoma	8.71e-06	5.4e-05	CbGpPWpGaD
Bortezomib—PSMA1—Signaling Pathways—TP53—glaucoma	8.68e-06	5.39e-05	CbGpPWpGaD
Bortezomib—CYP1A2—Metabolism—GSTT1—glaucoma	8.65e-06	5.36e-05	CbGpPWpGaD
Bortezomib—PSMD1—Signaling Pathways—TP53—glaucoma	8.64e-06	5.36e-05	CbGpPWpGaD
Bortezomib—CYP1A1—Metabolism—GSTM1—glaucoma	8.64e-06	5.36e-05	CbGpPWpGaD
Bortezomib—CYP3A4—Metabolism—TXN—glaucoma	8.61e-06	5.34e-05	CbGpPWpGaD
Bortezomib—PSMD2—Signaling Pathways—TP53—glaucoma	8.6e-06	5.33e-05	CbGpPWpGaD
Bortezomib—PSMB8—Signaling Pathways—VEGFA—glaucoma	8.59e-06	5.33e-05	CbGpPWpGaD
Bortezomib—CYP2C9—Metabolism of lipids and lipoproteins—PTGS2—glaucoma	8.16e-06	5.06e-05	CbGpPWpGaD
Bortezomib—CYP2D6—Metabolism—ABCA1—glaucoma	8.13e-06	5.04e-05	CbGpPWpGaD
Bortezomib—CYP2D6—Metabolism—CYP1B1—glaucoma	8.13e-06	5.04e-05	CbGpPWpGaD
Bortezomib—CYP2C9—Metabolism—ABCA1—glaucoma	8.06e-06	5e-05	CbGpPWpGaD
Bortezomib—CYP2C9—Metabolism—CYP1B1—glaucoma	8.06e-06	5e-05	CbGpPWpGaD
Bortezomib—CYP2C8—Metabolism—GSTM1—glaucoma	7.92e-06	4.91e-05	CbGpPWpGaD
Bortezomib—CYP1A1—Metabolism—MTHFR—glaucoma	7.64e-06	4.74e-05	CbGpPWpGaD
Bortezomib—PTGS1—Metabolism—NOS3—glaucoma	7.56e-06	4.69e-05	CbGpPWpGaD
Bortezomib—CYP1A1—Metabolism—APOE—glaucoma	7.11e-06	4.41e-05	CbGpPWpGaD
Bortezomib—CYP2C19—Metabolism—GSTM1—glaucoma	7.07e-06	4.38e-05	CbGpPWpGaD
Bortezomib—CYP1A1—Metabolism—CAV1—glaucoma	7.04e-06	4.37e-05	CbGpPWpGaD
Bortezomib—CYP2C8—Metabolism—MTHFR—glaucoma	7e-06	4.34e-05	CbGpPWpGaD
Bortezomib—CYP1A2—Metabolism of lipids and lipoproteins—PTGS2—glaucoma	6.97e-06	4.32e-05	CbGpPWpGaD
Bortezomib—PTGS1—Metabolism—PTGS2—glaucoma	6.91e-06	4.29e-05	CbGpPWpGaD
Bortezomib—CYP1A2—Metabolism—CYP1B1—glaucoma	6.89e-06	4.27e-05	CbGpPWpGaD
Bortezomib—CYP1A2—Metabolism—ABCA1—glaucoma	6.89e-06	4.27e-05	CbGpPWpGaD
Bortezomib—CYP3A4—Metabolism—GSTT1—glaucoma	6.67e-06	4.14e-05	CbGpPWpGaD
Bortezomib—PSMB5—Signaling Pathways—TP53—glaucoma	6.58e-06	4.08e-05	CbGpPWpGaD
Bortezomib—PSMB1—Signaling Pathways—TP53—glaucoma	6.58e-06	4.08e-05	CbGpPWpGaD
Bortezomib—PSMB2—Signaling Pathways—TP53—glaucoma	6.58e-06	4.08e-05	CbGpPWpGaD
Bortezomib—CYP2C8—Metabolism—APOE—glaucoma	6.52e-06	4.04e-05	CbGpPWpGaD
Bortezomib—CYP2D6—Metabolism—GSTM1—glaucoma	6.5e-06	4.03e-05	CbGpPWpGaD
Bortezomib—PSMB8—Signaling Pathways—TP53—glaucoma	6.49e-06	4.02e-05	CbGpPWpGaD
Bortezomib—CYP2C8—Metabolism—CAV1—glaucoma	6.46e-06	4e-05	CbGpPWpGaD
Bortezomib—CYP2C9—Metabolism—GSTM1—glaucoma	6.45e-06	4e-05	CbGpPWpGaD
Bortezomib—CYP2C19—Metabolism—MTHFR—glaucoma	6.25e-06	3.88e-05	CbGpPWpGaD
Bortezomib—CYP2C19—Metabolism—APOE—glaucoma	5.82e-06	3.61e-05	CbGpPWpGaD
Bortezomib—CYP2C19—Metabolism—CAV1—glaucoma	5.76e-06	3.57e-05	CbGpPWpGaD
Bortezomib—CYP2D6—Metabolism—MTHFR—glaucoma	5.75e-06	3.56e-05	CbGpPWpGaD
Bortezomib—CYP2C9—Metabolism—MTHFR—glaucoma	5.7e-06	3.53e-05	CbGpPWpGaD
Bortezomib—CYP1A2—Metabolism—GSTM1—glaucoma	5.51e-06	3.42e-05	CbGpPWpGaD
Bortezomib—CYP2D6—Metabolism—APOE—glaucoma	5.35e-06	3.32e-05	CbGpPWpGaD
Bortezomib—CYP1A1—Metabolism—NOS3—glaucoma	5.33e-06	3.3e-05	CbGpPWpGaD
Bortezomib—CYP3A4—Metabolism—CYP1B1—glaucoma	5.32e-06	3.3e-05	CbGpPWpGaD
Bortezomib—CYP3A4—Metabolism—ABCA1—glaucoma	5.32e-06	3.3e-05	CbGpPWpGaD
Bortezomib—CYP2C9—Metabolism—APOE—glaucoma	5.3e-06	3.29e-05	CbGpPWpGaD
Bortezomib—CYP2D6—Metabolism—CAV1—glaucoma	5.3e-06	3.29e-05	CbGpPWpGaD
Bortezomib—CYP2C9—Metabolism—CAV1—glaucoma	5.25e-06	3.26e-05	CbGpPWpGaD
Bortezomib—CYP2C8—Metabolism—NOS3—glaucoma	4.88e-06	3.03e-05	CbGpPWpGaD
Bortezomib—CYP1A1—Metabolism—PTGS2—glaucoma	4.87e-06	3.02e-05	CbGpPWpGaD
Bortezomib—CYP1A2—Metabolism—MTHFR—glaucoma	4.87e-06	3.02e-05	CbGpPWpGaD
Bortezomib—CYP1A2—Metabolism—APOE—glaucoma	4.53e-06	2.81e-05	CbGpPWpGaD
Bortezomib—CYP1A2—Metabolism—CAV1—glaucoma	4.49e-06	2.79e-05	CbGpPWpGaD
Bortezomib—CYP2C8—Metabolism—PTGS2—glaucoma	4.47e-06	2.77e-05	CbGpPWpGaD
Bortezomib—CYP2C19—Metabolism—NOS3—glaucoma	4.36e-06	2.7e-05	CbGpPWpGaD
Bortezomib—CYP3A4—Metabolism—GSTM1—glaucoma	4.25e-06	2.64e-05	CbGpPWpGaD
Bortezomib—CYP2D6—Metabolism—NOS3—glaucoma	4.01e-06	2.49e-05	CbGpPWpGaD
Bortezomib—CYP2C19—Metabolism—PTGS2—glaucoma	3.99e-06	2.47e-05	CbGpPWpGaD
Bortezomib—CYP2C9—Metabolism—NOS3—glaucoma	3.97e-06	2.46e-05	CbGpPWpGaD
Bortezomib—CYP3A4—Metabolism—MTHFR—glaucoma	3.76e-06	2.33e-05	CbGpPWpGaD
Bortezomib—CYP2D6—Metabolism—PTGS2—glaucoma	3.67e-06	2.27e-05	CbGpPWpGaD
Bortezomib—CYP2C9—Metabolism—PTGS2—glaucoma	3.63e-06	2.25e-05	CbGpPWpGaD
Bortezomib—CYP3A4—Metabolism—APOE—glaucoma	3.5e-06	2.17e-05	CbGpPWpGaD
Bortezomib—CYP3A4—Metabolism—CAV1—glaucoma	3.47e-06	2.15e-05	CbGpPWpGaD
Bortezomib—CYP1A2—Metabolism—NOS3—glaucoma	3.4e-06	2.11e-05	CbGpPWpGaD
Bortezomib—CYP1A2—Metabolism—PTGS2—glaucoma	3.11e-06	1.93e-05	CbGpPWpGaD
Bortezomib—CYP3A4—Metabolism—NOS3—glaucoma	2.62e-06	1.63e-05	CbGpPWpGaD
Bortezomib—CYP3A4—Metabolism—PTGS2—glaucoma	2.4e-06	1.49e-05	CbGpPWpGaD
